XCE853
Ovarian Cancer, Advanced Pancreatic Cancer
Pre-clinicalActive
Key Facts
Indication
Ovarian Cancer, Advanced Pancreatic Cancer
Phase
Pre-clinical
Status
Active
Company
About Oregon Therapeutics
Oregon Therapeutics is a preclinical-stage biotech focused on oncology, leveraging an onco-metabolism platform to develop PDI inhibitors. Its lead candidate, XCE853, is positioned as a first- and best-in-class therapy, with initial priority indications in ovarian and advanced pancreatic cancer. The company, led by a small team of industry veterans, aims to enter clinical trials within two years, targeting a significant unmet need in hard-to-treat cancers.
View full company profile